Novo Nordisk has fired the first “shot heard around the health care world.”
Rosiglitazone, which is used to treat type 2 diabetes, may increase the risk of heart problems.
Fresenius Kabi’s glucagon emergency kit is a cost-effective alternative to branded kit products.
The FDA posted results of its NDMA lab analysis of metformin products in the United States.
SGLT2 inhibitor therapy provided protective effects from cardiovascular (CV) events in patients with type 2 diabetes with or without established CV disease.
Eli Lilly plans to donate at least 200,000 KwikPens of its insulin to support lower-income communities.
Older adults with diabetes are experiencing declines in all-cause mortality rates, whereas younger adults continue to be affected more by the condition.
The FDA has approved semaglutide (Ozempic, Novo Nordisk) for the reduction of major adverse cardiovascular (CV) events in patients with type 2 diabetes and established CV disease.
Shingles vaccination recommended by CDC and ADCES.
Eli Lilly added additional affordability options for patients with diabetes who use certain insulin products.